Global Polymyalgia Rheumatica Industry Outlook 2025-2029: Market Set to Cross $1.72 Billion Milestone

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Polymyalgia Rheumatica Market Size By 2025?
Substantial expansion has been observed in the market pertaining to polymyalgia rheumatica recently, projecting an increase from $1.28 billion currently in 2024 to $1.36 billion in 2025, which reflects a compound annual growth rate (CAGR) of 5.9%. This upward trajectory throughout the historical timeframe is linked to several factors, including elevated levels of recognition among medical professionals, the increased administration of corticosteroids, the proliferation of specialized medical facilities, the arrival of novel biologic treatments, and expanding financial allocations for healthcare.

How Big Is the Polymyalgia Rheumatica Market Size Expected to Grow by 2029?
Forecasting robust expansion, the market concerning polymyalgia rheumatica is anticipated to reach a valuation of $1.72 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.1%; this upsurge over the projection timeline is fueled by increased utilization of biologic treatments, the widening scope of precision medicine approaches, swifter regulatory clearances for medications, more comprehensive insurance coverage, and the proliferation of clinical investigations. Key developments shaping this period involve the creation of combined treatment regimens, progress in tailoring medical care to individuals, ongoing refinement of precision medicine concepts, the incorporation of electronic health records into practice, and breakthroughs in identifying biological indicators.

View the full report here:
https://www.thebusinessresearchcompany.com/report/polymyalgia-rheumatica-global-market-report

Which Key Market Drivers Powering Polymyalgia Rheumatica Market Expansion and Growth?
Anticipated expansion in the need for treatments customized to the individual is projected to fuel the progression of the polymyalgia rheumatica market henceforth. Tailored medical intervention, which considers a person's specific genetic makeup, daily habits, and unique health status to yield superior results, defines personalized medicine. This escalating requirement stems from breakthroughs in genetic investigation, increasing patient desires for bespoke therapies, and enhancements in diagnostic tools. Deeper insights into individual genetic differences, courtesy of genetic research, facilitate the development of therapies precisely aimed at particular genetic indicators. Such an approach enables the selection of medications most likely to benefit a patient based on their individual traits, resulting in a treatment regimen that is both safer and more efficacious. Illustratively, data from the Personalised Medicine Coalition indicated that in 2023, the U.S. Food and Drug Administration granted approval for sixteen novel personalized therapies designed for individuals suffering from rare conditions, a significant increase from the six approvals recorded in 2022, as reported in February 2024. Consequently, this trend towards personalized medical care serves as a catalyst for the advancement of the polymyalgia rheumatica market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22103&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Polymyalgia Rheumatica Market?
Key participants within the polymyalgia rheumatica arena are concentrating efforts on creating sophisticated pharmaceuticals, exemplified by the development of interleukin-6 (IL-6) receptor antagonists, intended to furnish highly specific and more efficacious therapeutic pathways. These IL-6 receptor blockers represent biologic agents engineered to obstruct IL-6, which functions as a pivotal pro-inflammatory cytokine implicated in various autoimmune disorders; by impeding IL-6 activity, these therapies successfully mitigate inflammatory responses and alleviate clinical manifestations, thereby elevating the standard of living for individuals afflicted with PMR. A concrete example of this progress occurred in February 2023, when Sanofi, a healthcare enterprise headquartered in France, and the American biotech firm Regeneron Pharmaceuticals, Inc., revealed that the Food and Drug Administration (FDA) had given its assent to Kevzara (sarilumab) for routine adult PMR treatment in cases resistant to conventional corticosteroid therapy or where dose reduction proves unfeasible. Being the sole biologic agent authorized for this particular ailment, Kevzara functions through the suppression of IL-6-driven intercellular communication; this authorization stemmed from clinical evidence indicating that, across a full year (week 52), 28.3% of subjects receiving sarilumab sustained remission, a significantly higher proportion than the 10.3% observed in the placebo group. Kevzara is administered through a self-injection beneath the skin every fortnight and has prior regulatory clearance for managing moderate to severe active rheumatoid arthritis, while Sanofi's shares (ticker SNY) are presently valued on the NASDAQ exchange at $54.13.

What Are the Emerging Segments in the Polymyalgia Rheumatica Market?
The polymyalgia rheumaticamarket covered in this report is segmented -

1) By Treatment: Corticosteroids; Nonsteroidal Anti-Inflammatory Drugs; Disease-Modifying Antirheumatic Drugs; Biologics
2) By Route Of Administration: Oral; Intravenous; Subcutaneous
3) By Patient Type: Adult; Geriatric; Periatric
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:
1) By Corticosteroids: Prednisone; Methylprednisolone; Hydrocortisone; Dexamethasone
2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Naproxen; Aspirin; Celecoxib
3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate; Leflunomide; Sulfasalazine; Hydroxychloroquine
4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin-6 (IL-6) Inhibitors; B-Cell Inhibitors; Janus Kinase (JAK) Inhibitors

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=22103&type=smp

Who Are the Global Leaders in the Polymyalgia Rheumatica Market?
Major companies operating in the polymyalgia rheumatica market are AbbVie Inc., Sanofi S.A., Eli Lilly and Co., Regeneron Pharmaceuticals Inc., Mount Sinai, NYU Langone Health, Mayo Foundation for Medical Education and Research, Hartford HealthCare, Horizon Therapeutics plc, Massachusetts General Hospital, Brigham and Women's Hospital, Stanford Health Care, University Hospitals Bristol NHS Foundation Trust, Circle Health Group Ltd., Siloam Hospital, UC San Diego Health, Vejthani Hospital, Sparrow Pharmaceuticals Inc., Johns Hopkins Arthritis Center, Upstate University Hospital

Which are the Top Profitable Regional Markets for the Polymyalgia Rheumatica Industry?
Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2024. The regions covered in the polymyalgia rheumatica market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22103

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.